CORRECTION

Correction to: Carfentanil: a narrative review of its pharmacology and public health concerns

Carfentanil: étude narrative de sa pharmacologie et problématiques de santé publique

Jessica L. S. Leen, MD · David N. Juurlink, MD, PhD

Published online: 25 February 2019
© Canadian Anesthesiologists' Society 2019

Correction to: Can J Anesth/J Can Anesth
<https://doi.org/10.1007/s12630-018-01294-y>

In the article entitled: “Carfentanil: a narrative review of its pharmacology and public health concerns” published online and in the April 2019 issue of the *Journal*, Can J Anesth 2019; DOI: <https://doi.org/10.1007/s12630-019-01294-y>, the Figure showed the wrong structures for remifentanyl and carfentanyl. This is now corrected in the accompanying revised Figure and legend.

The original article can be found online at <https://doi.org/10.1007/s12630-019-01294-y>.

J. L. S. Leen, MD
Department of Medicine, Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre, G-106, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada

D. N. Juurlink, MD, PhD (✉)
Department of Medicine, Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre, G-106, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
e-mail: dnj@ices.on.ca

Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

Institute of Health Policy, Management, and Evaluation,
University of Toronto, Toronto, ON, Canada

Sunnybrook Research Institute, Toronto, ON, Canada

Figure Carfentanyl (a) belongs to the 4-anilidopiperidine class of synthetic opioids along with fentanyl (b) and remifentanyl (c) as well as sufentanyl, alfentanil. It has a carboxymethyl group in the fourth position of the piperidine ring of fentanyl

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.